Publication|Articles|January 21, 2026

Supplements and Featured Publications

  • Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran

Participating Faculty: Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran

Listen
0:00 / 0:00

Faculty

Steven W. Pipe, MD

Professor of Pediatrics and Pathology

University of Michigan

Ann Arbor, MI

Faculty Disclosures

The following have relevant commercial financial relationships or affiliations to disclose:

Steven W. Pipe, MD, reports the following relevant commercial financial relationships or affiliations in the past 12 months:

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer, BioMarin, Chugai, CSL Behring, HEMA Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Roche/Genentech/Spark Therapeutics, Sanofi, Star Therapeutics, and Takeda

LECTURE FEES AT THE INVITATION OF A COMMERCIAL SPONSOR

Chugai, Roche, Sanofi

MEETING/CONFERENCE ATTENDANCE

Sanofi

SCIENTIFIC ADVISORY BOARDS

Equilibra, GeneVentiv

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo